The Latest Breaking News from Medicare

Yevgeny Prigozhin launched a failed rebellion in Russia. Activists in Atlanta hold a week of action against a police training facility. An Alzheimer's drug could be approved soon, but hurdles remain.

The Food and Drug Administration is expected to grant full approval to the Alzheimer's drug lecanemab by July 6. But access to the drug may still be limited.

Currently, regular care like cleanings and fillings, or services like dentures or extractions, are the responsibility of beneficiaries.

A key drugmaker lobbying group has joined the legal fight against the federal government’s plan to negotiate Medicare drug prices

At its height, the COVID-19 pandemic disrupted well-established patterns of migration within Australia. Reports of a regional renaissance suggested city dwellers were moving to regional areas in droves. The governments of Tasmania, South Australia and the Northern Territory were also keen to promote new migration flows to reverse long-standing declines…

Letting third parties pay our bills pushes prices higher and limits our options.

The proposed budget calls for tax cuts for the uber-rich and an increase in the Social Security retirement age

No one really expected the pharmaceutical industry to lie down and take it when Congress authorized Medicare to start negotiating prices of the prescription drugs it buys for enrollees.

There are no drugs or treatments to cure Alzheimer’s disease, but emerging drugs may slow disease progression.